Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 21

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 21
---
 to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers. We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our Common Shares less attractive to investors. We are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other public companies that are not emerging growth companies. For as long as we remain an emerging growth company we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not “emerging growth companies.” These exemptions include:

| ● | not being required to comply with the auditor attestation requirements in 
 the assessment of our internal control over financial reporting;          |

| ● | Section 107 of the JOBS Act, which provides that an “emerging growth                                                                         
 company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended,      
 or the Securities Act, for complying with new or revised accounting standards. This means that an “emerging growth company”                  
 can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Given that we       
 currently report and expect to continue to report our financial results under IFRS as issued by IASB, we will not be able to avail ourselves 
 of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which        
 adoption of such standards is required by IASB;                                                                                              |

| ● | not being required to comply with any requirement that may be adopted by                                                                
 the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing 
 additional information about the audit and the financial statements;                                                                    |

| ● | reduced disclosure obligations regarding executive compensation; and |

| ● | exemptions from the requirements of holding a nonbinding advisory vote on                                 
 executive compensation and shareholder approval of any golden parachute payments not previously approved. |

14 We will remain an emerging growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenues of at least $1.235 billion; (ii) the